Selected research
Industry Research
Gene Therapy Products Industry Research Report 2026
Market perspective
The global Gene Therapy Products market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Gene Therapy Products is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Gene Therapy Products is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Gene Therapy Products is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Gene Therapy Products include Advantagene, Avalanche Bio, Bluebird Bio, Celladon, Dimension Therapeutics, Sangamo, Spark Therapeutics and Vical Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Gene Therapy Products market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Gene Therapy Products Market by Company
Advantagene
Avalanche Bio
Bluebird Bio
Celladon
Dimension Therapeutics
Sangamo
Spark Therapeutics
Vical Inc.
Gene Therapy Products Segment by Type
Ex vivo
In Vivo
Gene Therapy Products Segment by Application
Cardiovascular disease
Monogenic
Infectious disease
Cancer
Other
Gene Therapy Products Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gene Therapy Products market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Gene Therapy Products and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gene Therapy Products.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Gene Therapy Products manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Gene Therapy Products by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Gene Therapy Products in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Ex vivo
- In Vivo
Applications
- Cardiovascular disease
- Monogenic
- Infectious disease
- Cancer
- Other
Companies covered
- Advantagene
- Avalanche Bio
- Bluebird Bio
- Celladon
- Dimension Therapeutics
- Sangamo
- Spark Therapeutics
- Vical Inc.
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Gene Therapy Products Market Size (2021-2032)
- 2.2.2 Global Gene Therapy Products Sales (2021-2032)
- 2.2.3 Global Gene Therapy Products Market Average Price (2021-2032)
- 2.3 Gene Therapy Products by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Ex vivo
- 2.3.3 In Vivo
- 2.4 Gene Therapy Products by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Cardiovascular disease
- 2.4.3 Monogenic
- 2.4.4 Infectious disease
- 2.4.5 Cancer
- 2.4.6 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Gene Therapy Products Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Gene Therapy Products Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Gene Therapy Products Revenue of Manufacturers (2021-2026)
- 3.4 Global Gene Therapy Products Average Price by Manufacturers (2021-2026)
- 3.5 Global Gene Therapy Products Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Gene Therapy Products, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Gene Therapy Products, Product Type & Application
- 3.8 Global Manufacturers of Gene Therapy Products, Established Date
- 3.9 Global Gene Therapy Products Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Advantagene
- 4.1.1 Advantagene Company Information
- 4.1.2 Advantagene Business Overview
- 4.1.3 Advantagene Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Advantagene Gene Therapy Products Product Portfolio
- 4.1.5 Advantagene Recent Developments
- 4.2 Avalanche Bio
- 4.2.1 Avalanche Bio Company Information
- 4.2.2 Avalanche Bio Business Overview
- 4.2.3 Avalanche Bio Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Avalanche Bio Gene Therapy Products Product Portfolio
- 4.2.5 Avalanche Bio Recent Developments
- 4.3 Bluebird Bio
- 4.3.1 Bluebird Bio Company Information
- 4.3.2 Bluebird Bio Business Overview
- 4.3.3 Bluebird Bio Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Bluebird Bio Gene Therapy Products Product Portfolio
- 4.3.5 Bluebird Bio Recent Developments
- 4.4 Celladon
- 4.4.1 Celladon Company Information
- 4.4.2 Celladon Business Overview
- 4.4.3 Celladon Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Celladon Gene Therapy Products Product Portfolio
- 4.4.5 Celladon Recent Developments
- 4.5 Dimension Therapeutics
- 4.5.1 Dimension Therapeutics Company Information
- 4.5.2 Dimension Therapeutics Business Overview
- 4.5.3 Dimension Therapeutics Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Dimension Therapeutics Gene Therapy Products Product Portfolio
- 4.5.5 Dimension Therapeutics Recent Developments
- 4.6 Sangamo
- 4.6.1 Sangamo Company Information
- 4.6.2 Sangamo Business Overview
- 4.6.3 Sangamo Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sangamo Gene Therapy Products Product Portfolio
- 4.6.5 Sangamo Recent Developments
- 4.7 Spark Therapeutics
- 4.7.1 Spark Therapeutics Company Information
- 4.7.2 Spark Therapeutics Business Overview
- 4.7.3 Spark Therapeutics Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Spark Therapeutics Gene Therapy Products Product Portfolio
- 4.7.5 Spark Therapeutics Recent Developments
- 4.8 Vical Inc.
- 4.8.1 Vical Inc. Company Information
- 4.8.2 Vical Inc. Business Overview
- 4.8.3 Vical Inc. Gene Therapy Products Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Vical Inc. Gene Therapy Products Product Portfolio
- 4.8.5 Vical Inc. Recent Developments
5 Global Gene Therapy Products Market Scenario by Region
- 5.1 Global Gene Therapy Products Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Gene Therapy Products Sales by Region: 2021-2032
- 5.2.1 Global Gene Therapy Products Sales by Region: 2021-2026
- 5.2.2 Global Gene Therapy Products Sales by Region: 2027-2032
- 5.3 Global Gene Therapy Products Revenue by Region: 2021-2032
- 5.3.1 Global Gene Therapy Products Revenue by Region: 2021-2026
- 5.3.2 Global Gene Therapy Products Revenue by Region: 2027-2032
- 5.4 North America Gene Therapy Products Market Facts & Figures by Country
- 5.4.1 North America Gene Therapy Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Gene Therapy Products Sales by Country (2021-2032)
- 5.4.3 North America Gene Therapy Products Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Gene Therapy Products Market Facts & Figures by Country
- 5.5.1 Europe Gene Therapy Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Gene Therapy Products Sales by Country (2021-2032)
- 5.5.3 Europe Gene Therapy Products Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Gene Therapy Products Market Facts & Figures by Country
- 5.6.1 Asia Pacific Gene Therapy Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Gene Therapy Products Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Gene Therapy Products Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Gene Therapy Products Market Facts & Figures by Country
- 5.7.1 South America Gene Therapy Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Gene Therapy Products Sales by Country (2021-2032)
- 5.7.3 South America Gene Therapy Products Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Gene Therapy Products Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Gene Therapy Products Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Gene Therapy Products Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Gene Therapy Products Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Gene Therapy Products Sales by Type (2021-2032)
- 6.1.1 Global Gene Therapy Products Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Gene Therapy Products Sales Market Share by Type (2021-2032)
- 6.2 Global Gene Therapy Products Revenue by Type (2021-2032)
- 6.2.1 Global Gene Therapy Products Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Gene Therapy Products Revenue Market Share by Type (2021-2032)
- 6.3 Global Gene Therapy Products Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Gene Therapy Products Sales by Application (2021-2032)
- 7.1.1 Global Gene Therapy Products Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Gene Therapy Products Sales Market Share by Application (2021-2032)
- 7.2 Global Gene Therapy Products Revenue by Application (2021-2032)
- 7.2.1 Global Gene Therapy Products Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Gene Therapy Products Revenue Market Share by Application (2021-2032)
- 7.3 Global Gene Therapy Products Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Gene Therapy Products Value Chain Analysis
- 8.1.1 Gene Therapy Products Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Gene Therapy Products Production Mode & Process
- 8.2 Gene Therapy Products Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Gene Therapy Products Distributors
- 8.2.3 Gene Therapy Products Customers
9 Global Gene Therapy Products Analyzing Market Dynamics
- 9.1 Gene Therapy Products Industry Trends
- 9.2 Gene Therapy Products Industry Drivers
- 9.3 Gene Therapy Products Industry Opportunities and Challenges
- 9.4 Gene Therapy Products Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst